Assessment of Liver Cancer Response to TACE Using MultiHance-Enhanced MRI.

• Status: Completed
• Trial end date: 2013-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This research is being done to find out if using the contrast agent MultiHance can be used to show how a liver tumor responds to the chemotherapy given during Transcatheter Arterial Chemoembolization (TACE).

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
• Collaborator: Bracco Diagnostics, Inc

Criteria

Inclusion Criteria:

• Outpatients between the ages of 18 - 80 seen in the cardiovascular and interventional radiology clinic who are scheduled for TACE.

• International Normalized Ratio (INR) <1.4

• Platelet count > 80,000

Exclusion Criteria:

• Contraindications to TACE procedure

• Unable to have an MRI Scan

• Allergy or hypersensitivity reactions to gadolinium or any other ingredients, including benzyl alcohol

• Patients with sickle cell anemia , hemoglobinopathies and other hemolytic anemias

• Known clinical hypersensitivity or a history of asthma or allergic respiratory disorders

• Patients with advanced renal failure (those currently requiring dialysis or with a Glomerular Filtration Rate<15cc/min)

• Pregnancy